Status:
COMPLETED
Patients With Epilepsy Taking LAMICTAL Immediate-Release Who Switch To Extended-Release Formulation And Vice Versa
Lead Sponsor:
GlaxoSmithKline
Conditions:
Epilepsy
Eligibility:
All Genders
13+ years
Phase:
PHASE3
Brief Summary
Pharmacokinetic (PK) study to characterize changes in serum concentrations in epilepsy patients when switching from LAMICTAL immediate-release to extended-release and vice versa.
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Confident diagnosis of epilepsy.
- Currently on LAMICTAL and up to 2 concomitant AEDs (anti-epileptic drugs).
- Exclusion Criteria:
- Females of childbearing potential cannot be on hormonal contraceptives or hormone replacement therapy.
Exclusion
Key Trial Info
Start Date :
October 1 2005
Trial Type :
INTERVENTIONAL
End Date :
June 1 2006
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT00264615
Start Date
October 1 2005
End Date
June 1 2006
Last Update
September 23 2016
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Anniston, Alabama, United States, 36207
2
GSK Investigational Site
Sun City, Arizona, United States, 85351
3
GSK Investigational Site
Lexington, Kentucky, United States, 40503
4
GSK Investigational Site
Lexington, Kentucky, United States, 40536-0284